A single-arm, Phase I/2 study investigated the combination of tucidinostat, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with R/R AML. Here, CSF3 is linked to acute myeloid leukemia.